Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today shared initial clinical validation data for its breast cancer radiation signature, Profile for the Omission of Local Adjuvant Radiotherapy (POLAR), at the 2022 San Antonio Breast Cancer Symposium® (SABCS®). The meta-analysis of three independent, randomized clinical trials identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery.

POLAR is the first genomic signature that is both prognostic for the risk of local regional recurrence and predictive of radiotherapy benefit. The analysis found that patients at low risk for local regional recurrence following breast-conserving surgery did not benefit from radiotherapy (~25% of patients). SABCS selected this meta-analysis as part of its press program.

“Exact Sciences’ POLAR signature addresses a significant clinical need for those with early-stage, hormone receptor positive breast cancer, identifying which patients may benefit from radiotherapy and which may not,” said Rick Baehner, M.D., chief medical officer of Precision Oncology at Exact Sciences. “Like chemotherapy, radiation therapy has significant physical, mental, and monetary costs associated with it. These data are a critical step toward providing patients with a new tool to help ensure better breast cancer treatment decisions.”

Click here to read the full article.